Paper - WANFANG MED ONLINE

You Position: Home > Paper

微球栓塞剂在肝细胞肝癌中的应用及研究进展

( views:41, downloads:392 )

Author:: No author available

Journal Title:: National Medical Journal of China

Issue:: 11

DOI:: 10.3760/cma.j.issn.0376-2491.2015.11.018

Key Word:: No keyword available

Abstract：肝细胞肝癌(HCC)是最常见的恶性肿瘤之一,其病死率仅次于胃癌、肺癌[1-3].肝动脉化疗栓塞术(TACE)则为中晚期HCC首选的姑息性治疗方法[1-2].而栓塞材料一直是临床研究的热点.近年来,各种微球栓塞剂得到迅猛发展,取得了较好的疗效[4-6].微球的定义是高分子材料形成的微小球状体、球形或类球形,直径一般在1～ 900μm之间,其中直径＜ 500 nm的称为纳米微球[7].根据微球的性质及作用分为两大类:单纯微球及载体微球.面对众多的栓塞微球,如何个体化的选择栓塞材料已成为一个新的问题.因此,本文就临床上常用的微球的特点、临床疗效及不良反应作一综述.

Reference

[1]邵海波,张曦彤,李红,等.栓塞微球在肝癌介入治疗中的应用[J].2008,(11).
[2]孙伟,周纯武,李忱瑞.海藻酸钠微球栓塞剂在肿瘤治疗中的应用现状[J].2009,(1).
[3]邢冬娟,徐爱民.微球在肝细胞癌经导管肝动脉化疗栓塞术治疗中的应用及研究进展[J].2011,(12).
[4]高杰,朱继业.卫生部《原发性肝癌诊疗规范（2011年版）》解读[J].2012,(8).
[5]涂建飞,纪建松,吴发宗,等.射频消融联合131碘肿瘤细胞核人鼠嵌合单克隆抗体治疗原发性肝癌的疗效分析[J].2014,(45).
[6]纪建松,滕皋军,宋晶晶,等.肝癌靶向载药纳米粒治疗的研究进展[J].2011,(1).
[7]孙伟,王永涛,史仲华,等.海藻酸钠微球联合碘化油栓塞治疗原发性肝癌的疗效分析[J].2012,(8).
[8]相建峰.中药栓塞剂在原发性肝癌介入治疗中的应用[J].2011,(6).
[9]Bruix,J.,Gores,G.J.,Mazzaferro,V..Hepatocellular carcinoma: Clinical frontiers and perspectives[J].2014,63(5).
[10].Chemoembolization decreases drop-off risk of hepatocellular carcinoma patients on the liver transplant list[J].2011,34(6).
[11]Caridi,J.G.,Real,M.I.,O'Grady,E.,etc.Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded dc bead (DEBDOX): Technical recommendations[J].2012,35(5).
[12]Iaccarino G,Strigari L,Benassi M,etc.Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations.[J].2010,51(9).
[13]Verhagen,R.,Ladd,S.C.,Sotiropoulos,G.C.,etc.Selective and sequential transarterial chemoembolization: Survival in patients with hepatocellular carcinoma[J].2012,81(9).
[14]Sangro,B.,I?arrairaegui,M.,Bilbao,J.I..Radioembolization for hepatocellular carcinoma[J].2012,56(2).
[15]Wang XD,Tan J,Li B,etc.Dose delivery estimated by bremsstrahlung imaging and partition model correlated with response following intra-arterial radioembolization with 32P-glass microspheres for the treatment of hepatocellular carcinoma.[J].2010,14(5).
[16]Vandecaveye V,Heye S,Verslype C,etc.A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma.[J].2011,34(7).
[17]Goffredo V,Gadaleta CD,Ranieri G,etc.Yttrium-90 (90Y) in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009).[J].2011,80(3).
[18]Pelage JP,Laurent A,Wassef M,etc.Uterine artery embolization in sheep: comparison of acute effects with polyvinyl alcohol particles and calibrated microspheres.[J].2002,224(2).
[19]Willis SL,Woods D,Esparza J,etc.Development of "imageable" beads for transcatheter embolotherapy.[J].2010,21(6).
[20]Zajko AB,Amesur NB,Carr BI.Chemo-embolization for unresectable hepatocellular carcinoma with different sizes of embolization particles.[J].2008,53(5).
[21]Andreana,L.,Isgrò,G.,Marelli,L.,etc.Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds: Trans-arterial radio-embolisation of HCC[J].2012,38(6).
[22]Huang,K.,Zhou,Q.,Wang,R.,etc.Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma[J].2014,29(5).
[23]Prajapati,H.J.,Spivey,J.R.,Hanish,S.I.,etc.mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)[J].2013,24(4).
[24]Chrisman HB,Baker TB,Chen R,etc.Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort.[J].2010,255(3).
[25]Lambert, B.,Sturm, E.,Mertens, J.,etc.Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4?years experience at the Ghent University Hospital[J].2011,38(12).
[26]Takayasu,K..Transarterial chemoembolization for hepatocellular carcinoma over three decades: Current progress and perspective[J].2012,42(4).
[27]Han, Shilong,Zhang, Xiaoping,Zou, Liling,etc.Does Drug-Eluting Bead Transcatheter Arterial Chemoembolization Improve the Management of Patients with Hepatocellular Carcinoma? A Meta-Analysis.[J].2014,9(8).
[28]Ana Maria, Crissien,Catherine, Frenette.Current management of hepatocellular carcinoma.[J].2014,10(3).
[29]Z P, Yan,G, Lin,H Y, Zhao,etc.An experimental study and clinical pilot trials on yttrium-90 glass microspheres through the hepatic artery for treatment of primary liver cancer.[J].1993,72(11).
[30]M.D. Ferrer Puchol,C. la Parra,E. Esteban,etc.Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma[J].2011,53(3).
[31]宋玉芳,赵京芳,宋玉平.海藻酸钠微球联合碘化油在TACE中的应用[J].2013,(15).
[32]Bouma,E.,Pomoni,M.,Malagari,K.,etc.Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: Five-year survival analysis[J].2012,35(5).
[33]Della Vigna P,Orgera G,Pedicini V,etc.Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up.[J].2010,33(3).
[34]Salem,R.,Gilbertsen,M.,Butt,Z.,etc.Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization[J].2013,11(10).
[35]Mario Scartozzi,Svegliati Gianluca Baroni,Luca Faloppi,etc.Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis[J].2010,29(1).